HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21

Benzinga · 09/15/2023 10:11
HC Wainwright & Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $19 to $21.